ONCONasdaq StockholmHealth CareIFRS · SEK

Oncopeptides

Oncopeptides is a Swedish biopharmaceutical company focused on developing and commercializing therapies for difficult-to-treat hematological diseases. The company is known for its proprietary Peptide-Drug Conjugate (PDC) platform, which has shown promise in treating multiple myeloma and is being expanded to other indications such as glioblastoma. Oncopeptides has achieved significant market access in Europe, particularly in Italy and Spain, and is actively pursuing opportunities in Japan. The company's flagship product, Pepaxti, has driven substantial sales growth, reflecting its strong demand in key markets.

Ask about the company
Revenue71.1m SEK
+124.7 %y/y
Operating profit (EBIT)-225m SEK
+20.8 %y/y
EBIT margin-315.9%
+579.9 ppy/y
Net income-65.2m SEK
+77.1 %y/y

Fiscal year 2025 · change from previous year

Development 2020–2025

-2,000-1,500-1,000-5000500m SEK2020: 0.00 m SEK2020: EBIT -1,591 m SEK20202021: 118 m SEK2021: EBIT -1,421 m SEK20212022: 8.4 m SEK2022: EBIT -349 m SEK20222023: 35 m SEK2023: EBIT -253 m SEK20232024: 32 m SEK2024: EBIT -283 m SEK20242025: 71 m SEK2025: EBIT -225 m SEK202571-225
RevenueOperating profit (EBIT)
Ask Clarifo about Oncopeptides

Business

Share of revenue
Pharmaceuticals70 %

Includes Pepaxti and other drug products

Research and Development20 %

Focuses on PDC platform and new indications

Market Access Services10 %

Facilitates drug approval and commercialization

Customers

Oncopeptides primarily serves healthcare providers and institutions specializing in hematology and oncology. The company's main customers include hospitals and clinics that treat patients with multiple myeloma and other hematological malignancies. In Europe, Oncopeptides has established a strong presence, particularly in Italy and Spain, where it has secured market access for Pepaxti. The company is also targeting the Japanese market through strategic partnerships with local pharmaceutical firms. Oncopeptides' customers value the innovative therapies that address high unmet medical needs, offering new treatment options for complex diseases.

Healthcare Providers

Purchase Pepaxti for treating multiple myeloma

Pharmaceutical Partners

Engage in licensing and distribution agreements

Research Institutions

Collaborate on PDC platform development

Strategy

Oncopeptides is focused on expanding its Peptide-Drug Conjugate (PDC) platform to address new indications beyond multiple myeloma, such as glioblastoma. The company aims to achieve positive cash flow by 2027 by optimizing its operations and focusing on high-potential markets. Strategic priorities include securing market access in key regions, enhancing the product pipeline, and forming strategic partnerships in Japan. Oncopeptides is also streamlining its operations in Germany to achieve profitability at the country level by 2026. These strategic initiatives are designed to strengthen the company's competitive position and drive long-term growth.

Expand PDC platformMedium term

To address new high-value indications

Achieve positive cash flowLong term

To ensure financial sustainability

Market accessShort term

To increase sales and market presence

Geography

Q4/2025

Oncopeptides is headquartered in Stockholm, Sweden, and has a significant presence in the European market, particularly in Italy and Spain, where it has successfully launched its flagship product, Pepaxti. The company is also exploring opportunities in Japan, having engaged in advanced negotiations with a local pharmaceutical company. While Europe remains the primary market, Oncopeptides is strategically expanding its geographic footprint to include Asia. The company's operations are supported by subsidiaries in Germany and other European countries, facilitating market access and commercialization efforts.

Europe100 %

Risks

Oncopeptides faces several risks, including regulatory challenges in securing market access for its products in new regions, which can delay commercialization efforts. The company's financial performance is also sensitive to fluctuations in demand for Pepaxti, particularly in key markets like Germany. Additionally, geopolitical risks, such as changes in healthcare policies in Europe, could impact market dynamics. Oncopeptides must also manage the risks associated with its strategic expansion into Japan, where negotiations with local partners are ongoing. The company continuously evaluates these risks to mitigate their potential impact on its operations and financial performance.

Sorted by severity
LowMediumHighLowMediumHighImpact →Likelihood →Regulatory challenges1Demand fluctuations3
Impact is the risk’s severity and likelihood how probable it is over the next few years, both assessed from the company’s reports. Numbers match the list.
  1. Regulatory challengesImpact: HighLikelihood: Medium

    Delays in market access

  2. Geopolitical risksImpact: High

    Impact on healthcare policies

  3. Demand fluctuationsImpact: MediumLikelihood: Medium

    Affects revenue stability

Ask Clarifo about Oncopeptides

Accounting

Judgemental items
Revenue recognition timing

Impacts reported sales and profitability

Cash flow management

Essential for funding growth initiatives

Estimates and provisions

Affects financial statement accuracy

Similar listed companies

Publicly listed companies with a comparable business focus.

Swedish Orphan Biovitrum

SOBI · Health Care

Orion Oyj

ORNBV · Drug Manufacturers - General

Cantargia

CANTA · Health Care

Bicycle Therapeutics plc

BCYC · Pharmaceutical Preparations

GENELUX Corp

GNLX · Pharmaceutical Preparations

PepGen Inc.

PEPG · Pharmaceutical Preparations

Last updated: 24/09/2026

Oncopeptides (ONCO) Revenue, Earnings & Financials 2025 – Clarifo